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Abstract
Background: Prothrombin complex concentrate (PCC) is widely used to reverse the action of direct oral anticoagulants
(DOACs) in accordance with current guidelines and because of a lack of specific reversal agents. Indications, clinical
characteristics and patient outcomes of patients might differ in comparison to reversal of vitamin K antagonists where
reversal with PCC is well established.
Methods: Our cohort study explores patient characteristics, indications and clinical outcomes for reversal of all DOAC
patients receiving PCC at our university emergency department from 01.06.2012 to 01.07.2017, in comparison with
patients on VKA.
Results: Out of 199,982 consultations, we studied 346 patients who were given PCC for reversal of either DOAC (n = 74)
or VKA (n = 272). The most common reason for treatment was acute bleeding; in 86.7% of both groups. 37.
3% of bleeding was traumatic (p = 0.666). The most frequent bleeding location was intracranial (61.6%, p = 0.881).
Gastrointestinal bleeding was more often found in the DOAC group (18.9% vs. 8.8%, p = 0.014). More erythrocyte
concentrates (ECs) were given to DOAC patients with blood transfusion (p = 0.014). Tranexamic acid was used more
often in DOAC patients than in VKA patients (28.4% vs. 7.4%, p < 0.001). No significant group differences were found for
the following patient outcomes: in-hospital mortality, ICU stay, and length of stay at the ICU or in hospital.
Conclusion: In DOAC treated patients, PCC was applied more often because of gastrointestinal bleeding and patients
received higher numbers of ECs as well as tranexamic acid. No differences were observed with regard to important
clinical outcomes.
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Background
The main drawback when dealing with direct oral an-
ticoagulants (DOACs) is the risk of bleeding. Simply
stopping DOACs might be adequate for some clinical
situations because of the short half-life of these drugs
[1]. Nevertheless, anticoagulant activity must be rap-
idly reversed for life-threatening bleeding, emergency
surgery or procedures. In contrast to dabigatran –
where the specific reversal agent idarucizumab is
available [2] –, no specific reversal agent for the fac-
tor Xa inhibitors apixaban, edoxaban and rivaroxaban
has yet been approved in most countries. In cases of
life-threatening and uncontrollable bleeding, adexanet
alfa has recently been approved by the FDA for the
reversal of apixaban and rivaroxaban but not edoxa-
ban [3]. Clinical experience with this new reversal
agent is still sparse and practical real-life indications
are yet to be established [4]. Most clinicians currently
use prothrombin complex concentrate (PCC) for re-
versal of factor Xa inhibitors, despite the lack of pro-
spective evidence in accordance with current
recommendations and guidelines [5–7]. Prothrombin
complex concentrate might counteract the anti-Xa ef-
fect of rivaroxaban by restoring thrombin generation
[8]. A recent multinational survey has identified large
gaps in the knowledge of the management of
DOAC-associated bleeding [9].
In contrast to DOAC reversal, PCC is well established
as the reversal agent for VKA because of its rapid onset
of action, small volume load and the low risk of transfu-
sion reactions [5, 6].
While the prevalence of DOACs is growing and spe-
cific reversal agents are coming on the market, there is
still little evidence or clinical experience with DOAC re-
versal. Therefore, further insights into the practice and
outcome of DOAC reversal are needed.
Thus, our study aims to compare the characteristics of
patients in the following two groups: those receiving
PCC for non-specific reversal of DOAC and those re-
ceiving PCC for reversal of VKA. We also compared the
indications for reversal in the two patient groups, to-
gether with the clinical ED outcomes (blood products
given, ICU/IMC admission, length of stay (ICU/IMC
and in-hospital), and in-hospital mortality).
Methods
Study design and setting
This retrospective cohort study was set in the adult ED
of Bern University Hospital (Inselspital), Switzerland, a
self-contained, interdisciplinary department, treating pa-
tients aged 18 years and older. The adult ED is a level 1
centre. Over 40,000 consultations are annually registered
and treated at the ED.
Inclusion criteria
The analysis included all patients on DOAC or VKA
who received PCC - irrespective of the cause – and
were admitted from 01.06.2012 to 01.07.2017 to our ED.
Our hospital follows a specific published guideline for
the reversal of oral anticoagulants in the case of acute
bleeding incidences or urgent procedures [5]. In our
study population, the indication for the use of PCC in
the individual case was provided by the attending phys-
ician. In our hospital, only four-factor PCC is used and
therefore included in this study.
Exclusion criteria
The following exclusion criteria were used:
 No documentation of the application of PCC
 No oral anticoagulation medication documented in
the medical report or insufficient information to
determine anticoagulation status
Study outcomes
Study outcomes were in-hospital mortality and proced-
ural outcomes (e.g. hospitalisation, length of hospital
stay [hours], the need for ICU admission during hospi-
talisation and length of ICU [hours]), as well as the need
for and amount of blood products given.
Data collection and extraction
All medical reports, including patient history and diag-
nosis, clinical findings, medication given at the ED and
on arrival, as well as procedure in and after the ED are
electronically recorded for every patient and stored in
the computerised ED patient database (E-Care, ED
2.1.3.0, Turnhout, Belgium).
Firstly, a broad keyword search was performed through
all medical reports between 01.06.2012 to 01.07.2017 -
containing all the substance classes and brand names of
oral anticoagulants approved in Switzerland (substance
classes: rivaroxaban, dabigatran, apixaban, and edoxaban,
phenprocoumon, warfarin, and acenocoumarol), com-
bined with the logic operator “OR”.
The application of medication, especially PCC, is thor-
oughly documented in the database. Secondly, we ex-
cluded all results of the keyword search that did not
receive PCC – the application of PCC is electronically
stored in the system. Thirdly, manual screening (done by
JE) was performed through the medical report of the
remaining consultations, excluding all consultations
without current intake of an oral anticoagulation (e.g.
paused medication), giving the final study population.
Variables describing the patient’s anticoagulation, the pa-
tient and bleeding characteristics, were extracted from
the medical report (done by JE). All investigated out-
comes were obtained from the patient database.
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Exposure
The exposure was to all sorts of Swiss medic-approved
direct oral anticoagulation drugs. We assigned the direct
oral anticoagulants (rivaroxaban, dabigatran, apixaban,
and edoxaban) to the DOAC group. For comparison, we
used the VKA group, comprising all patients under ac-
tive treatment with phenprocoumon, warfarin, or
acenocoumarol.
Data analysis
The statistical analysis was performed with Stata® 13.1
(StataCorp, The College Station, Texas, USA). The study
compared patients on DOAC or VKA, which were re-
versed by PCC. Categorical variables were expressed as
absolute numbers, accompanied by relative numbers.
Continuous variables were expressed as medians with
interquartile ranges. The two groups of patients (DOAC
or VKA) were compared with respect to the reported clin-
ical ED outcomes (in-hospital mortality, hospitalisation,
length of hospital stay [hours], ICU admission, and length
of ICU stay [hours]). Fisher’s exact tests were used to
compare categorical variables and the Wilcoxon rank sum
test to compare continuous variables. A p-value of < 0.05
was defined as significant.
Ethics
The present study is registered with the ethics commit-
tee of Canton Bern, Switzerland (073/2015). Because of
the use of coded routine care patient data, no informed
consent is needed according to Swiss law.
Results
In total, 14,684 of 199,982 consultations (7.2%) were
identified through the anticoagulation key-word search
over the five-year study period (Fig. 1).
PPC was not administered in 14,332 consultations, so
352 consultations were analysed in full text. After manu-
ally screening the medications, six consultations had to
be excluded as no current DOAC intake was docu-
mented. Thus, the analysis included 346 consultations
that received PCC for reversal of DOAC or VKA medi-
cation - divided into 272 VKA and 74 DOAC patients.
Most of the patients in the DOAC group were on
Fig. 1 Abbreviations: DOAC, direct oral anticoagulant; VKA, Vitamin K antagonists. (D)OAC, (direct) oral anticoagulant; PPC, prothrombin
complex concentrate
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rivaroxaban (90.5%, n = 67). Five patients (6.7%) took
apixaban, and one patient each dabigatran or edoxaban.
Patient characteristics
The median age was 77 (IQR 69–82) years in the DOAC
group and 79 (72–84) years in the VKA group (p = 0.064).
Fifty-seven percent of the patients were males, without a
significant group difference (p = 0.518).
Apart from a diagnosis of carcinoma (DOAC 21.6%,
VKA: 7.7%, p = 0.001), there were no significant differ-
ences between the two anticoagulation groups in regard
to comorbidities (Tables 1 and 2).
The most common indication for anticoagulation
was atrial fibrillation in both groups (64.5%). There
was no significant difference between the anticoagula-
tion indication (p = 0.090), additional platelet therapy
(p = 0.328), or additional heparin therapy (p = 0.643),
see Table 2. In our population, bleeding events were
not associated with additional platelet aggregation
inhibitor therapy (p = 0.964).
Consultation characteristics and indications for reversal
An acute life-threatening triage was coded significantly
more often (p = 0.024) in the DOAC group (51.4%) than
in the VKA group (31.2%), whereas less urgent triage was
uncommon in both groups (DOAC: 0.0% vs. VKA: 1.5%).
Haemoglobin, platelets, and creatinine did not differ sig-
nificantly between the groups (p = 0.094, 0.432, 0.832).
The median INR was 1.2 (IQR 1.1–1.4) in the DOAC
group and 2.3 (1.6–3.1) in the VKA group (p < 0.001).
In both groups, the most common indication for re-
versal was bleeding (DOAC: 93.2% vs. VKA: 84.9%);
other indications were endoscopy (total: 2.9%) or inva-
sive procedures e.g. drainage need or centesis (total:
5.2%) and emergency operation (total: 5.2%), without a
significant group difference (p = 0.245). There was no
significant difference (p = 0.666) between the proportion
of trauma consultations (DOAC: 35.1% vs. VKA: 37.9%),
see Table 3.
Bleeding characteristics
As the main indication for reversal was bleeding (86.7%),
we further investigated bleeding localisation in all pa-
tients (Table 4). The most common location was intra-
cranial (61.6%), followed by gastrointestinal bleeding
(11.0%) and superficial bleeding (6.4%). Apart from
gastrointestinal bleeding - which was found in 18.9% of
the DOAC consultations and in 8.8% of the VKA consul-
tations (p = 0.014) -, no significant differences between
the groups were found in regard to the bleeding
location.
Blood products and reversal
The numbers of blood products and reversals that were
given in the anticoagulation groups are shown in Table 5.
The number of additionally transfused erythrocyte con-
centrates (ECs) was 20.3% in the DOAC group and
12.1% in the VKA group (p = 0.073), with significant dif-
ferences regarding the number of ECs given - with a
higher number in the DOAC group (p = 0.014). The
Table 1 Patient characteristics
Total (n = 346) DOAC (n = 74) Vitamin K antagonist (n = 272) p
Age, [median (IQR)] 78.0 (70–84) 77.0 (69–82) 79.0 (72–84) 0.064
Gender (male) 199 (57.5) 45 (60.8) 154 (56.6) 0.518
Comorbidities
Hypertension 146 (42.2) 30 (40.5) 116 (42.6) 0.745
Diabetes 63 (18.2) 10 (13.5) 53 (19.5) 0.238
Peripheral arterial disease 26 (7.5) 6 (8.1) 20 (7.4) 0.827
Hypertensive cardiopathy 75 (21.7) 17 (23.0) 58 (21.3) 0.760
Coronary heart disease 91 (26.3) 14 (18.9) 77 (28.3) 0.104
Valvular cardiopathy 75 (21.7) 15 (20.3) 60 (22.1) 0.741
Chronic kidney disease 99 (28.6) 25 (33.8) 74 (27.2) 0.267
Liver insufficiency 6 (1.7) 2 (2.7) 4 (1.5) 0.472
COPD 21 (6.1) 6 (8.1) 15 (5.5) 0.407
Venous thromboembolism 61 (17.6) 11 (14.9) 50 (18.4) 0.481
Aortic disease 15 (4.3) 3 (4.1) 12 (4.4) 0.893
Stroke 48 (13.9) 9 (12.2) 39 (14.3) 0.631
Carcinoma 37 (10.7) 16 (21.6) 21 (7.7) 0.001
Coagulopathy 13 (3.8) 1 (1.4) 12 (4.4) 0.220
Abbreviation: DOAC direct oral anticoagulants, COPD chronic obstructive pulmonary disease
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number of PCC units or platelet concentrates given did
not differ between the groups (p = 0.346, p = 0.307, re-
spectively). Tranexamic acid in addition to PCC was
given significantly more often in the DOAC group
(28.4% vs. 7.4%, p < 0.001).
ED outcomes
There was a high number of ICU admissions in both
groups (67.6% vs. 59.9%, p = 0.231). The in-hospital mor-
tality was 9.5% in the DOAC group and 5.5% in the
VKA group (p = 0.218). There were no significant group
differences between the length of stay at the ICU
(p = 0.391) or in the hospital (p = 0.756), Table 6.
Discussion
Overview
The characteristics of patients who received PCC for
non-specific reversal of DOAC were found to be similar
to those who underwent VKA reversal. The vast major-
ity of reversals in both OAC groups were performed
Table 2 Anticoagulation characteristics
Total (n = 346) DOAC (n = 74) Vitamin K antagonist (n = 272) p
Anticoagulation indication
Not specified 27 (7.8) 10 (13.5) 17 (6.2)
Atrial fibrillation 223 (64.5) 48 (64.9) 175 (64.3)
Thromboembolic event 74 (21.4) 13 (17.6) 61 (22.4)
Mechanical heart-valve 17 (4.9) 1 (1.4) 16 (5.9)
Coagulopathy 5 (1.4) 2 (2.7) 3 (1.1) 0.090
Additional platelet aggregation inhibitor therapy
None 285 (82.4) 62 (83.8) 223 (82.0)
Acetylsalicylic acid 44 (12.7) 9 (12.2) 35 (12.9)
Clopidogrel 13 (3.8) 1 (1.4) 12 (4.4)
Acetylsalicylic acid + Clopidogrel 4 (1.2) 2 (2.7) 2 (0.7) 0.328
Additional heparin 7 (2.0) 1 (1.4) 6 (2.2) 0.643
Abbreviation: DOAC direct oral anticoagulants
Table 3 Consultation characteristics and indications for reversal
Total (n = 346) DOAC (n = 74) Vitamin K antagonist (n = 272) p
Triage
Acute life threating problem 123 (35.5) 38 (51.4) 85 (31.2)
High urgency 142 (41.0) 25 (33.8) 117 (43.0)
Urgency 70 (20.2) 10 (13.5) 60 (22.1)
Less urgency 4 (1.2) 0 (0.0) 4 (1.5)
Missing 7 (2.0) 1 (1.4) 6 (2.2) 0.024
Laboratory valuesa
Haemoglobin (g/l) 122 (105–136) 117.5 (97–135) 122 (107–136) 0.094
Creatinine (μmol/l) 90 (71–123) 85.0 (71–118) 91 (71–125) 0.432
Platelets (G/l) 209 (168–262) 199.5 (169–271) 211 (168–254) 0.832
INR 2.0 (1.3–2.9) 1.2 (1.1–1.4) 2.3 (1.6–3.1) < 0.001
Trauma 129 (37.3) 26 (35.1) 103 (37.9) 0.666
Outpatient discharge 2 (0.6) 1 (1.4) 1 (0.4) 0.322
Indication for reversal
Bleeding 300 (86.7) 69 (93.2) 231 (84.9)
Endoscopy 10 (2.9) 1 (1.4) 9 (3.3)
Drainage, centesis, puncture 18 (5.2) 3 (4.1) 15 (5.5)
Emergency operation 18 (5.2) 1 (1.4) 17 (6.2) 0.245
Abbreviation: DOAC direct oral anticoagulants, INR international normalised ratio
aData available for 94.2, 99.1, 83.2%, or 99.1% for the values haemoglobin, creatinine, platelets, or INR
Müller et al. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine           (2019) 27:48 Page 5 of 9
because of acute bleeding; about a third were in trauma
patients. The main indication for reversal in both groups
was intracranial bleeding, but significantly more DOAC
patients underwent reversal for gastrointestinal bleeding
than with VKA patients. A higher percentage of patients
with DOAC received tranexamic acid during ED treat-
ment, mostly because of intracranial bleeding. Patients
with blood transfusion on DOACs needed larger number
of ECs.
Patient and consultation characteristics receiving PCC for
non-specific reversal of DOAC compared to VKA
The age of patients receiving PCC for OAC reversal did
not differ significantly between the DOAC and VKA
groups. Also, no significant differences were found in
comparison of all comorbidities between the two groups -
apart from carcinoma. The greater percentage of patients
with cancer in patients with DOAC receiving reversal is
interesting, given the fact that the discussion about DOAC
therapy and the effectiveness of DOAC in cancer patients
as well as the bleeding risk in this population is still on-
going [10]. The efficacy and safety in cancer patients in a
large randomised, controlled Hokusai VTA trail could re-
cently be shown for edoxaban [11]. Unfortunately because
of the retrospective extraction of routine emergency docu-
mentation with limited data, no statement about possible
reasons for DOAC prescription in those cancer patients
or the timing of prescription or cancer diagnosis can be
made.
Another risk factor for bleeding events is co-medication
with platelet aggregation inhibitor therapy, as shown in real
life as well as in phase II studies of all DOACs as well as for
VKA [12–16]. In our study, a relevant number of patients
were under antiplatelet co-medication but without differ-
ence between the two groups. This co-medication was not
associated with bleeding events.
Patient with DOAC reversal were found to be triaged to
a more acute triage category. The reason for this impres-
sion remains unclear, especially given the fact that we did
not find any difference in type of bleeding or trauma. It
Table 4 Bleeding locations
Total (n = 346) DOAC (n = 74) Vitamin K antagonist (n = 272) p
Intracranial 213 (61.6) 45 (60.8) 168 (61.8) 0.881
Upper/lower gastrointestinal 38 (11.0) 24 (18.9) 14 (8.8) 0.014
Superficial 22 (6.4) 4 (5.4) 18 (6.6) 0.705
Extremity 17 (4.9) 2 (2.7) 15 (5.5) 0.321
Abdominal 13 (3.8) 2 (2.7) 11 (4.0) 0.591
Thorax 11 (3.2) 4 (5.4) 7 (2.6) 0.218
Eye 6 (1.7) 1 (1.4) 5 (1.8) 0.776
Retroperitoneal 5 (1.4) 1 (1.4) 4 (1.5) 0.939
Haematuria 3 (0.9) 1 (1.4) 2 (0.7) 0.612
Epistaxis 2 (0.6) 0 (0.0) 2 (0.7) 0.459
Oral 1 (0.3) 0 (0.0) 1 (0.4) 0.601
Abbreviation: DOAC direct oral anticoagulants
Table 5 Blood products and reversal agents
Total (n = 346) DOAC (n = 74) Vitamin K antagonist (n = 272) p
PCC (units), [median (IQR)] 2100 (1800-2400) 2000 (1700–3000) 2100 (1800-2400) 0.346
ECs given 48 (13.9) 15 (20.3) 33 (12.1) 0.073
Number of ECs
1 23 (6.7) 6 (8.2) 17 (6.2)
2 14 (4.1) 3 (4.1) 11 (4.0)
3 7 (2.0) 4 (5.5) 3 (1.1)
4 2 (0.6) 2 (2.7) 0 (0.0)
5 2 (0.6) 0 (0.0) 2 (0.7) 0.014
Platelet concentrates 5 (1.4) 2 (2.7) 3 (1.1) 0.307
Fresh frozen plasma 19 (5.5) 6 (8.1) 13 (4.8) 0.265
Tranexamic acid 41 (11.8) 21 (28.4) 20 (7.4) < 0.001
Abbreviation: DOAC direct oral anticoagulants, ECs erythrocyte concentrates, IQR interquartile range, PCC prothrombin complex concentrate
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might be hypothesised that physicians are more cautious
when treating bleeding emergencies under DOAC because
they might have less experience with DOAC bleeding than
with the well-known VKA. This uncertainty with the
management of DOAC-associated bleeding was recently
described by Shaw et al., especially for emergency physi-
cians and anaesthetists, who are also the main groups of
physicians responsible for the treatment decisions in our
study [9].
Indications for reversal
The vast majority of patients in both OAC groups re-
ceived reversal because of traumatic or non-traumatic
acute bleeding, but only the minority for urgent proce-
dures or surgery. The probable explanation is that
non-vital interventions can be postponed until the anti-
coagulant effect of DOAC has disappeared or until the
effect of VKA is slowly reversed with vitamin K rather
than PPC. This avoids the possible prothrombotic effect
of all reversal therapy. By far the most common indica-
tion for reversal was intracranial bleeding in both patient
groups, as the risk benefit is absolutely clear in those pa-
tients and no other way of bleeding control is available.
Patients with DOAC therapy received reversal more
often because of gastrointestinal bleeding in comparison
to patients with VKA. It is known that high-dose dabiga-
tran and rivaroxaban, the predominant DOAC in our
population, as well as high-dose edoxaban, have a
greater risk of gastrointestinal bleeding compared to
warfarin because of local and systemic effects [17, 18].
With our study data, no statement about the absolute
incidence of gastrointestinal bleeding can be made.
Clinical ED outcomes
Blood products given
Our investigation showed no significant difference in the
number of patients who received ECs. There is a trend
for more ECs in DOAC patients, although this does not
attain significance (may be due to the limited sample
size). In contrast to this, in cases when ECs were given,
a significantly higher number of ECs were used in the
DOAC group than in the VKA group. The reason for
this is unclear. It cannot simply be explained with differ-
ences in the initial Hb, which we found to be
non-significantly different. The recommendations for EC
transfusion given in our in-house guidelines are the
same for all types of oral anticoagulants [5]. In our insti-
tution during study period, targets for EC transfusion
were haemoglobin > 70 g/l and mean arterial pressure >
50mmHg for healthy patients; haemoglobin > 90 g/l and
mean arterial pressure > 60–70 mmHg for patients with
traumatic brain injury or coronary artery disease.
More patients with DOAC reversal received tranex-
amic acid than in the VKA group, especially patients
with intracranial bleeding. The application of tranexamic
acid is in line with our in-house guidelines and with
guidelines that generally recommend tranexamic acid to-
gether with PPC for DOAC reversal [5–7]. About half of
the intracranial bleedings were non-traumatic. The re-
cent TICH-2 study could not show any improvement in
functional status for non-traumatic intracranial bleeding
after the administration of tranexamic acid compared to
placebo after 90 days, but could not exclude small effects
in subgroups [19]. For the subgroup of patients with
DOAC, the effect is still unclear, as the TICH-NOAC
study (NCT02866838) investigating tranexamic acid in
spontaneous intracranial bleeding patients with DOAC
therapy is still ongoing.
Procedural outcomes
None of the procedural outcomes (ICU admission, LOS
ICU or hospital overall and in-hospital mortality) that
were compared in our study differed significantly be-
tween the DOAC and VKA groups. Because of the small
group sizes, it is likely that our investigation is under-
powered to demonstrate differences in mortality and fur-
ther research is necessary.
Implications for the future
With the upcoming reversal agent for factor Xa antago-
nists, adexanet alfa, a discussion about indications for
reversal is warranted given the missing experiences and
presumably the remarkable costs of the specific antidote.
For this discussion, it is important to understand in
which situations in current practice, DOAC reversal is
performed, especially because in many situations stop-
ping DOAC therapy might be enough. Other possibilities
will have to be explored, such as measuring the level of
DOAC medication, in order to identify patient groups
that might have the highest benefit from the specific
Table 6 Procedural outcomes
Total (n = 346) DOAC (n = 74) Vitamin K antagonist (n = 272) p
ICU admission 213 (61.6) 50 (67.6) 163 (59.9) 0.231
LOS ICU [hours] 16.8 (0–43) 22.0 (0–58) 16.5 (0–41) 0.391
LOS hospital [hours] 120.8 (65–225) 117.6 (72–227) 122.3 (64–224) 0.756
In-hospital mortality 22 (6.4) 7 (9.5) 15 (5.5) 0.218
Abbreviation: DOAC direct oral anticoagulants, ICU intensive care unit, LOS length of stay
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antidote. DOAC medication levels measurements are
already available in many departments. In contrast to
routine DOAC level measurements, for life-threatening
bleeding a fast point-of-care measurement would be ne-
cessary to guide reversal. At the moment, in our setting
for severe but not life-threating, DOAC levels are ob-
tained before reversal.
Limitations
As our investigation is limited to one single centre, the
transferability to other patient populations remains un-
known and warrants further investigations.
Documentation bias cannot be completely excluded in
any retrospective investigation, despite careful review of
all included data. Nevertheless, this bias can be assumed
to be equally distributed between all patient groups and
therefore will most likely not compromise the conclu-
sion of this study.
The distribution of the different DOACs, with rivarox-
aban being the DOAC with the highest prevalence in
our data, reflects the DOAC distribution in our popula-
tion [20]. Because of the limited prevalence of patients
with dabigatran in our population, idarucizumab is used
rarely in our population and is therefore not included in
this study. During the study period 4 patients received
idarucizumab for dabigatran reversal in our department.
Our experience with idarucizumab in a patient with im-
paired kidney function has been previously published
[21]. The general prevalence of patients on anticoagula-
tion is also mirrored in group size of anticoagulation vs.
no-anticoagulation group.
Further prospective multi-centre investigations are
recommended. These should include more patients on
different DOACs and ensure sufficient power for spe-
cific outcomes. Because of the limited numbers, no
statement about the specific DOACs can be made
and all DOACs are analysed together. DOAC levels
should be measured, in order to evaluate the influ-
ence of possible medication interactions [22] or medi-
cation compliance.
Conclusion
Age and gender of patients receiving PCC for
non-specific reversal of DOAC are comparable to pa-
tients on VKA. The vast majority of reversals in both
OAC groups are performed because of acute bleeding,
most frequently intracranial bleeding. A third of rever-
sals were done in trauma patients. Reversal of gastro-
intestinal bleeding was performed more often in DOAC
than in VKA. The reason for this and the need of higher
amounts of ECs in DOAC patients with blood transfu-
sion are unexplained.
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